Keywords: shire, pharmaceuticals, pretax, profits, jump, biochem, merger
Shire Pharmaceuticals pretax profits jump 50% as BioChem merger is delayed
Article | 27 April 2001
Shire Pharmaceuticals of the UK has reported a 31% rise in revenues forfirst-quarter 2001 to $155.6 million, while pretax profits excluding charges climbed 50% ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- US Supreme Court says patent settlement can "sometimes" be illegal
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
- Additional indications in Japan for Roche's Avastin and Astellas' Prograf
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
